Product Images Levetiracetam

This is a description of Levetiracetam Injection, USP 500mg/5mL for intravenous use only that must be diluted prior to administration. The medication is provided in 10 single-dose vials and each vial contains 500mg of levetiracetam along with other chemicals for pH adjustment. The recommended dosage and other information can be found on the package insert. It is distributed by Novadoz Pharmaceuticals LLC and was issued in October 2022.*

This is a description of Levetiracetam Injection, a drug that is available in a 500mg/5 mL solution for intravenous use only, distributed by Novadoz Pharmaceuticals LLC and manufactured by MSN Laboratories Private Limited. Each vial of the solution contains 500mg levetiracetam, 8.2mg sodium acetate trinhydrate, and glacial acetic acid. This drug should be stored at 25°C (77°F) and must be diluted prior to administration for intravenous use only. The drug should be administered using single-dose vials and any unused portion should be discarded. More information and complete dosage recommendations can be found in the package insert.*

This seems to be a table or chart showing the percentage of patients in a medical study who were given a placebo versus those given different doses of Levetiracetam. However, without additional context it is difficult to provide a more detailed description.*

The given text appears to be a set of numerical values and medical jargon. It is not possible to provide any useful description without proper context.*

This appears to be a table or chart showing two percentages, "39.4%" and "14.4%", associated with a placebo group and a "Levetiracetam 3000 mg/day" group. However, without additional context or information it is not possible to determine the significance or meaning of these percentages.*

The given text appears to be a chart showing percentages from 45% to 0%, with a break (-) at 30%. Below the break, percentages continue from 25% to 0%. The chart also lists two groups with their respective sample sizes (97 and 101) and their corresponding percentages at 19.6% and 44.6%. However, without context or additional information, it is not possible to determine the meaning or purpose of the chart.*

The given text is from a clinical trial report, presenting the percentage of effectiveness of two treatments - placebo and levetiracetam. The success rate for the placebo treatment was 43.1%, while for levetiracetam it was 19.6%. The numbers are probably representing the percentage of patients who responded positively to these treatments. The result was obtained on a sample of 51 patients for the placebo group and 58 for the levetiracetam group.*

The text seems to show a table with percentages ranging from 100% to 70% and two groups called "Placebo" and "Levetiracetam" with the number of participants in each group. However, it is not possible to deduce the context or purpose of the data from this information.*

Levetiracetam Injection is a prescription drug that comes in a 5mL single-dose vial with 500mg per 5mL (100mg/mL) strength. It is used only for intravenous administration and must be diluted before use. The drug is manufactured in Telangana, India, by MSN Laboratories Private Limited, and distributed in the United States by Novadoz Pharmaceuticals LLC. It requires a prescription and must be stored at 25°C (77°F). For information on how to use the drug, check the package insert.*